ACOG Guideline Revisions Boost Myriad’s BRCA Test
This article was originally published in The Pink Sheet Daily
Executive Summary
Pharma-like direct-to-consumer ads should help boost diagnostic’s sales, and AstraZeneca trials could establish use with PARP inhibitors.